Myka Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.15 M
- Company Age 7 Year, 4 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth -21.76%
- Profit Growth 79.36%
- Ebitda -56.96%
- Net Worth -0.94%
- Total Assets -3.30%
About Myka Pharmaceuticals
Myka Pharmaceuticals Private Limited (MPPL) is a Private Limited Indian Non-Government Company incorporated in India on 09 October 2017 (Seven years and four months 9 days old ). Its registered office is in Agra, Uttar Pradesh, India.
The Company is engaged in the Business Services Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.15 M, as per Ministry of Corporate Affairs (MCA) records.
Sahil Abbas, Rais Abbas, and Wasim Abbas serve as directors at the Company.
Company Details
-
Location
Agra, Uttar Pradesh, India
-
Telephone
+91-XXXXXXXXXX
- Email Address
-
Website
-
-
Social Media
-
Corporate Identity Details
-
CIN/LLPIN
U74999UP2017PTC097641
-
Company No.
097641
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
09 Oct 2017
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Kanpur
Industry
Who are the key members and board of directors at Myka Pharmaceuticals?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sahil Abbas
|
Director | 09-Oct-2017 | Current |
|
Rais Abbas
|
Director | 09-Oct-2017 | Current |
|
Wasim Abbas
|
Director | 09-Oct-2017 | Current |
Financial Performance of Myka Pharmaceuticals.
Myka Pharmaceuticals Private Limited, for the financial year ended 2022, experienced significant reduction in revenue, with a 21.76% decrease. The company also saw a substantial improvement in profitability, with a 79.36% increase in profit. The company's net worth dipped by a decrease of 0.94%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Myka Pharmaceuticals?
Unlock access to Myka Pharmaceuticals's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Myka Pharmaceuticals?
Unlock and access historical data on people associated with Myka Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Myka Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Myka Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.